Brief: Brickell Biotech Completes Patient Enrollment In Phase 3 Study Of Sofpironium Bromide Gel To Treat Primary Axillary Hyperhidrosis

Fresh Tracks Therapeutics

27/04/2021 12:36

April 27 (Reuters) - Brickell Biotech Inc  BBI.O :
    * BRICKELL BIOTECH COMPLETES PATIENT ENROLLMENT IN U.S.
PHASE 3
PIVOTAL CARDIGAN I STUDY OF SOFPIRONIUM BROMIDE GEL, 15% FOR THE
TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS
    * BRICKELL BIOTECH INC - PHASE 3 PIVOTAL CARDIGAN II STUDY
EXCEEDS
50% ENROLLMENT
    * BRICKELL BIOTECH INC - TOPLINE RESULTS FOR PHASE 3 PIVOTAL
CARDIGAN I AND CARDIGAN II CLINICAL STUDIES EXPECTED IN Q4 2021

Source text for Eikon:  ID:nGNX1r4XVp 
Further company coverage:  BBI.O 

 ((Reuters.Briefs@thomsonreuters.com;))